Selected research
Industry Growth & Trends
Global Somatostatin Analogue Drug Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Somatostatin Analogue Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Somatostatin Analogue Drug market include Teva Pharmaceutical Industries Ltd., Novartis AG, Eli Lilly & Co., Pfizer Inc., Tarveda Therapeutics Inc., Ipsen Group, F. Hoffmann-La Roche Ltd., Chiasma and Camurus AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Somatostatin Analogue Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Somatostatin Analogue Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Somatostatin Analogue Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Somatostatin Analogue Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Somatostatin Analogue Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Somatostatin Analogue Drug Market by Company
Teva Pharmaceutical Industries Ltd.
Novartis AG
Eli Lilly & Co.
Pfizer Inc.
Tarveda Therapeutics Inc.
Ipsen Group
F. Hoffmann-La Roche Ltd.
Chiasma
Camurus AB
Boehringer Ingelheim International GmbH
Somatostatin Analogue Drug Segment by Type
Octreotide
Lanreotide
Pasireotide
Somatostatin Analogue Drug Segment by Application
Acromegaly
Neuroendocrine Tumor (NET)
Others
Somatostatin Analogue Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Analogue Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Analogue Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Analogue Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Somatostatin Analogue Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Octreotide
- Lanreotide
- Pasireotide
Applications
- Acromegaly
- Neuroendocrine Tumor (NET)
- Others
Companies covered
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Eli Lilly & Co.
- Pfizer Inc.
- Tarveda Therapeutics Inc.
- Ipsen Group
- F. Hoffmann-La Roche Ltd.
- Chiasma
- Camurus AB
- Boehringer Ingelheim International GmbH
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Somatostatin Analogue Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Somatostatin Analogue Drug Market Size by Region (2021-2032)
- 1.4.1 Global Somatostatin Analogue Drug Market Size by Region (2021-2026)
- 1.4.2 Global Somatostatin Analogue Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Somatostatin Analogue Drug Market Size (2021-2032)
- 1.5.1 North America Somatostatin Analogue Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Somatostatin Analogue Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Somatostatin Analogue Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Somatostatin Analogue Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Somatostatin Analogue Drug Market Size Growth Rate (2021-2032)
2 Somatostatin Analogue Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Octreotide
- 2.1.2 Lanreotide
- 2.1.3 Pasireotide
- 2.2 Global Somatostatin Analogue Drug Market Size by Type
- 2.2.1 Global Somatostatin Analogue Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Somatostatin Analogue Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Somatostatin Analogue Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Somatostatin Analogue Drug Market Size by Regions
- 2.3.1 North America Somatostatin Analogue Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Somatostatin Analogue Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Somatostatin Analogue Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Somatostatin Analogue Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Somatostatin Analogue Drug Market Size Breakdown by Type (2021-2026)
3 Somatostatin Analogue Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Acromegaly
- 3.1.2 Neuroendocrine Tumor (NET)
- 3.1.3 Others
- 3.2 Global Somatostatin Analogue Drug Market Size by Application
- 3.2.1 Global Somatostatin Analogue Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Somatostatin Analogue Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Somatostatin Analogue Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Somatostatin Analogue Drug Market Size by Regions
- 3.3.1 North America Somatostatin Analogue Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Somatostatin Analogue Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Somatostatin Analogue Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Somatostatin Analogue Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Somatostatin Analogue Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Somatostatin Analogue Drug Industry Trends
- 4.2 Somatostatin Analogue Drug Industry Drivers
- 4.3 Somatostatin Analogue Drug Industry Opportunities and Challenges
- 4.4 Somatostatin Analogue Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Somatostatin Analogue Drug Revenue (2021-2026)
- 5.2 Global Somatostatin Analogue Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Somatostatin Analogue Drug Key Company Headquarters & Area Served
- 5.4 Global Somatostatin Analogue Drug Company, Product Type & Application
- 5.5 Global Somatostatin Analogue Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Somatostatin Analogue Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Somatostatin Analogue Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Somatostatin Analogue Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva Pharmaceutical Industries Ltd.
- 6.1.1 Teva Pharmaceutical Industries Ltd. Company Information
- 6.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 6.1.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Portfolio
- 6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 6.2 Novartis AG
- 6.2.1 Novartis AG Company Information
- 6.2.2 Novartis AG Business Overview
- 6.2.3 Novartis AG Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis AG Somatostatin Analogue Drug Product Portfolio
- 6.2.5 Novartis AG Recent Developments
- 6.3 Eli Lilly & Co.
- 6.3.1 Eli Lilly & Co. Company Information
- 6.3.2 Eli Lilly & Co. Business Overview
- 6.3.3 Eli Lilly & Co. Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Eli Lilly & Co. Somatostatin Analogue Drug Product Portfolio
- 6.3.5 Eli Lilly & Co. Recent Developments
- 6.4 Pfizer Inc.
- 6.4.1 Pfizer Inc. Company Information
- 6.4.2 Pfizer Inc. Business Overview
- 6.4.3 Pfizer Inc. Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Pfizer Inc. Somatostatin Analogue Drug Product Portfolio
- 6.4.5 Pfizer Inc. Recent Developments
- 6.5 Tarveda Therapeutics Inc.
- 6.5.1 Tarveda Therapeutics Inc. Company Information
- 6.5.2 Tarveda Therapeutics Inc. Business Overview
- 6.5.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Portfolio
- 6.5.5 Tarveda Therapeutics Inc. Recent Developments
- 6.6 Ipsen Group
- 6.6.1 Ipsen Group Company Information
- 6.6.2 Ipsen Group Business Overview
- 6.6.3 Ipsen Group Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Ipsen Group Somatostatin Analogue Drug Product Portfolio
- 6.6.5 Ipsen Group Recent Developments
- 6.7 F. Hoffmann-La Roche Ltd.
- 6.7.1 F. Hoffmann-La Roche Ltd. Company Information
- 6.7.2 F. Hoffmann-La Roche Ltd. Business Overview
- 6.7.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Portfolio
- 6.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 6.8 Chiasma
- 6.8.1 Chiasma Company Information
- 6.8.2 Chiasma Business Overview
- 6.8.3 Chiasma Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Chiasma Somatostatin Analogue Drug Product Portfolio
- 6.8.5 Chiasma Recent Developments
- 6.9 Camurus AB
- 6.9.1 Camurus AB Company Information
- 6.9.2 Camurus AB Business Overview
- 6.9.3 Camurus AB Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Camurus AB Somatostatin Analogue Drug Product Portfolio
- 6.9.5 Camurus AB Recent Developments
- 6.10 Boehringer Ingelheim International GmbH
- 6.10.1 Boehringer Ingelheim International GmbH Company Information
- 6.10.2 Boehringer Ingelheim International GmbH Business Overview
- 6.10.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Portfolio
- 6.10.5 Boehringer Ingelheim International GmbH Recent Developments
7 North America
- 7.1 North America Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Somatostatin Analogue Drug Market Size by Country (2021-2026)
- 7.3 North America Somatostatin Analogue Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Somatostatin Analogue Drug Market Size by Country (2021-2026)
- 8.3 Europe Somatostatin Analogue Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Somatostatin Analogue Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Somatostatin Analogue Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Somatostatin Analogue Drug Market Size by Country (2021-2026)
- 10.3 South America Somatostatin Analogue Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Somatostatin Analogue Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst